MicroRNA-24-3p Targets Notch and Other Vascular Morphogens to Regulate Post-ischemic Microvascular Responses in Limb Muscles.
3' Untranslated Regions
/ genetics
Animals
Cell Differentiation
/ genetics
Extremities
/ pathology
Human Umbilical Vein Endothelial Cells
/ metabolism
Humans
Ischemia
/ genetics
Male
Mice
MicroRNAs
/ genetics
Muscle, Skeletal
/ metabolism
Receptor, Notch1
/ genetics
Receptors, Notch
/ genetics
beta Catenin
/ genetics
Notch
angiogenesis
endothelial cells
limb ischemia
miR-24-3p
β-catenin
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 Mar 2020
03 Mar 2020
Historique:
received:
28
01
2020
revised:
19
02
2020
accepted:
20
02
2020
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
15
12
2020
Statut:
epublish
Résumé
MicroRNAs (miRs) regulate complex processes, including angiogenesis, by targeting multiple mRNAs. miR-24-3p-3p directly represses eNOS, GATA2, and PAK4 in endothelial cells (ECs), thus inhibiting angiogenesis during development and in the infarcted heart. miR-24-3p is widely expressed in cardiovascular cells, suggesting that it could additionally regulate angiogenesis by acting on vascular mural cells. Here, we have investigated: 1) new miR-24-3p targets; 2) the expression and the function of miR-24-3p in human vascular ECs; 3) the impact of miR-24-3p inhibition in the angiogenesis reparative response to limb ischemia in mice. Using bioinformatics target prediction platforms and 3'-UTR luciferase assays, we newly identified Notch1 and its Delta-like ligand 1 (Dll1) to be directly targeted by miR-24-3p. miR-24-3p was expressed in human ECs and pericytes cultured under normal conditions. Exposure to hypoxia increased miR-24-3p in ECs but not in pericytes. Transfection with a miR-24-3p precursor (pre-miR-24-3p) increased miR-24-3p expression in ECs, reducing the cell survival, proliferation, and angiogenic capacity. Opposite effects were caused by miR-24-3p inhibition. The anti-angiogenic action of miR-24-3p overexpression could be prevented by simultaneous adenovirus (Ad)-mediated delivery of constitutively active Notch intracellular domain (NICD) into cultured ECs. We next demonstrated that reduced Notch signalling contributes to the anti-angiogenic effect of miR-24-3p in vitro. In a mouse unilateral limb ischemia model, local miR-24-3p inhibition (by adenovirus-mediated miR-24-3p decoy delivery) restored endothelial Notch signalling and increased capillary density. However, the new vessels appeared disorganised and twisted, worsening post-ischemic blood perfusion recovery. To better understand the underpinning mechanisms, we widened the search for miR-24-3p target genes, identifying several contributors to vascular morphogenesis, such as several members of the Wingless (Wnt) signalling pathway, β-catenin signalling components, and VE-cadherin, which synergise to regulate angiogenesis, pericytes recruitment to neoformed capillaries, maturation, and stabilization of newly formed vessels. Among those, we next focussed on β-catenin to demonstrate that miR-24-3p inhibition reduces β-catenin expression in hypoxic ECs, which is accompanied by reduced adhesion of pericytes to ECs. In summary, miR-24-3p differentially targets several angiogenesis modulators and contributes to autonomous and non-autonomous EC crosstalk. In ischemic limbs, miR-24-3p inhibition increases the production of dysfunctional microvessels, impairing perfusion. Caution should be observed in therapeutic targeting of miR-24-3p.
Identifiants
pubmed: 32138369
pii: ijms21051733
doi: 10.3390/ijms21051733
pmc: PMC7084374
pii:
doi:
Substances chimiques
3' Untranslated Regions
0
MIRN24 microRNA, human
0
MicroRNAs
0
NOTCH1 protein, human
0
Receptor, Notch1
0
Receptors, Notch
0
beta Catenin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : British Heart Foundation
ID : RG/15/5/31446
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have no conflicting financial interest.
Références
Development. 1991 Apr;111(4):1029-43
pubmed: 1879348
Cell. 2011 Sep 16;146(6):873-87
pubmed: 21925313
J Cell Biol. 2003 Jun 23;161(6):1163-77
pubmed: 12810700
Adv Exp Med Biol. 2018;1109:111-124
pubmed: 30523593
Nat Cell Biol. 2015 Sep;17(9):1145-57
pubmed: 26302406
Cancer Lett. 2019 Jan;440-441:211-222
pubmed: 30393198
Circ Res. 2008 Jul 18;103(2):e15-26
pubmed: 18566344
Nat Cell Biol. 2011 Aug 14;13(10):1244-51
pubmed: 21841793
Development. 2005 Apr;132(8):1819-30
pubmed: 15772135
Genes Dev. 2000 Jun 1;14(11):1343-52
pubmed: 10837027
Trends Endocrinol Metab. 2015 Sep;26(9):502-8
pubmed: 26197955
Am J Transl Res. 2016 Jul 15;8(7):3179-87
pubmed: 27508039
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
J Exp Med. 2011 Mar 14;208(3):549-60
pubmed: 21383058
Cardiovasc Res. 2001 Feb 16;49(3):507-21
pubmed: 11166264
Mol Ther. 2009 Jun;17(6):1109-15
pubmed: 19352324
Biochim Biophys Acta. 2009 Feb;1793(2):290-9
pubmed: 19000719
Nature. 1997 Nov 27;390(6658):410-3
pubmed: 9389482
J Biol Chem. 2011 Apr 15;286(15):13741-53
pubmed: 21349836
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
Development. 2014 Apr;141(8):1757-66
pubmed: 24715464
Proc Natl Acad Sci U S A. 2011 May 17;108(20):8287-92
pubmed: 21536891
PLoS One. 2009;4(4):e5033
pubmed: 19343226
J Cell Mol Med. 2008 Sep-Oct;12(5A):1426-31
pubmed: 18624759
Sci Rep. 2015 Nov 05;5:16151
pubmed: 26537366
J Angiogenes Res. 2010 Jan 26;2(1):3
pubmed: 20298529
Circulation. 2011 Aug 9;124(6):720-30
pubmed: 21788589
J Cell Biochem. 2007 Nov 1;102(4):840-7
pubmed: 17891779
Mol Ther. 2013 Jul;21(7):1390-402
pubmed: 23774796
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Nat Rev Mol Cell Biol. 2011 Aug 23;12(9):551-64
pubmed: 21860391
Genome Res. 2013 Apr;23(4):604-15
pubmed: 23335364
Clin Biochem Rev. 2017 Nov;38(3):131-142
pubmed: 29332977
Mol Cancer. 2014 Feb 11;13:28
pubmed: 24517586
Circ Res. 2012 Feb 17;110(4):530-5
pubmed: 22282195
Dev Cell. 2005 Nov;9(5):617-28
pubmed: 16256737
Nat Commun. 2014 Oct 31;5:5214
pubmed: 25358394
Angiogenesis. 2019 Feb;22(1):167-183
pubmed: 30238211
Blood. 2008 Sep 1;112(5):1720-9
pubmed: 18559979
Nature. 2012 Mar 18;484(7392):110-4
pubmed: 22426001
Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9462-7
pubmed: 12080144
J Am Soc Nephrol. 2014 Dec;25(12):2717-29
pubmed: 24854275
J Cell Biochem. 2012 Feb;113(2):629-39
pubmed: 21956839
F1000Prime Rep. 2015 Mar 03;7:26
pubmed: 25926977
Cancer Metastasis Rev. 2000;19(1-2):1-5
pubmed: 11191048
Cell Rep. 2014 Aug 21;8(4):1077-92
pubmed: 25131208
J Cell Biol. 2010 Apr 19;189(2):325-38
pubmed: 20404113
Dev Cell. 2009 Jan;16(1):70-82
pubmed: 19154719
Dev Cell. 2009 Feb;16(2):196-208
pubmed: 19217422
Gene. 2010 Feb 1;451(1-2):1-5
pubmed: 19944134
Circ Res. 2011 Sep 30;109(8):894-906
pubmed: 21868695
Biochim Biophys Acta. 2016 Feb;1863(2):303-13
pubmed: 26592459
Nature. 2007 Feb 15;445(7129):776-80
pubmed: 17259973
Vasc Med. 2008 Aug;13(3):281-91
pubmed: 18687766
Mol Ther Nucleic Acids. 2016 Aug 23;5(8):e354
pubmed: 27741223
Dev Cell. 2017 Mar 27;40(6):552-565.e5
pubmed: 28350988
Microcirculation. 2019 Aug;26(6):e12549
pubmed: 30974486